Biotronik study
This article was originally published in The Gray Sheet
Executive Summary
BIOSOLVE-1 trial evaluating the firm's Drug-Eluting Absorbable Metal Scaffold in patients with de novo coronary artery lesions is under way, with the first implant occurring July 27, Biotronik reports. The first-of-its kind scaffold, made with biodegradeable magnesium, combines the advantages of a drug-eluting stent and a reliable degradation profile that allows the vessel to return slowly to its natural physiology, according to the company. The device may be a safer option than drug-eluting stents, which remain in the body and have potential complications like late stent thrombosis, Biotronik suggests